protein tyrosine phosphatases

protein tyrosine phosphatases

A family of phosphate hydrolyzing enzymes that help regulate signaling between cells. Some diseases linked to abnormalities in protein tyrosine phosphatases include allergies, asthma, diabetes mellitus, obesity, and Alzheimer's disease.
References in periodicals archive ?
It is an enzyme - one in a "superfamily" of 105 called protein tyrosine phosphatases (PTPs) -- that perform the essential biochemical task of removing phosphate groups from amino acids called tyrosines in other proteins.
1) Protein tyrosine phosphatases, are a group of enzymes that remove phosphate groups from phosphorylated tyrosine residues on proteins.
The opening chapters review the chemical principles of protein binding, FRET detection techniques, protein tyrosine phosphatases, and the formation of oligomers.
Protein tyrosine kinases (PTK) are the cellular enzymes that phosphorylate the tyrosine residues in proteins while protein tyrosine phosphatases (PTP) are the enzymes responsible for the selective dephosphorylation of tyrosine residues.
The contributors review research findings on protein tyrosine phosphatases, interleukin-21, class switch recombination, thymus organogenesis, somatic hypermutation, and T follicular helper cells.
VioQuest's oncology portfolio includes: Xyfid(TM) (1% uracil topical), for the treatment of dry skin conditions and manage the burning and itching associated with various dermatoses; VQD-002 (triciribine phosphate monohydrate), a targeted inhibitor of Akt activation; and Lenocta(TM) (sodium stibogluconate), an inhibitor of certain protein tyrosine phosphatases such as SHP-1, SHP-2, and PTP1B.
VQD-001 has shown in preclinical studies to specifically inhibit protein tyrosine phosphatases (PTPs), a family of enzymes believed to play a crucial role in solid tumor formation.
ATPase, acid phosphatase, alkaline phosphatase, and protein tyrosine phosphatases.
Montreal, Canada), a biopharmaceutical company focussed on signaling pathways modulated by protein tyrosine phosphatases.
VioQuest's oncology portfolio includes: Xyfid(TM) (1% uracil topical), for the treatment and prevention of Hand-Foot Syndrome, a common side effect from certain chemotherapy treatments, and to treat dry skin conditions and manage the burning and itching associated with various dermatoses; VQD-002 (triciribine phosphate monohydrate), a targeted inhibitor of Akt activation; and Lenocta(TM) (sodium stibogluconate), an inhibitor of certain protein tyrosine phosphatases such as SHP-1, SHP-2, and PTP1B.
A leader in personalized therapeutics, VioQuest has two targeted therapeutics in clinical trials: VQD-001, an inhibitor of specific protein tyrosine phosphatases, has shown compelling preclinical activity in both renal and melanoma cancers, and VQD-002, which has been shown to inhibit the phosphorylation of Akt seen in abnormal levels in breast, ovarian, colorectal, pancreatic cancers and leukemia.

Full browser ?